Oral Abstract Session:
168. Novel Therapies for Superbugs
Friday, October 5, 2018: 2:00 PM-3:15 PM
Room: S 158

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID, Pediatric ID

Moderator:  Yohei Doi, MD, PhD, University of Pittsburgh Medical Center

2:30 PM
Treatment of recurrent Clostridium difficile infection with SER-109 reduces gastrointestinal carriage of antimicrobial resistance genes.
Christopher Ford, PhD; Matthew Henn, Ph.D.; Jessica Bryant, PhD; Liyang Diao, Ph.D.; Jennifer Wortman, Ph.D.; Amelia Tomlinson, PhD; Kevin Litcofsky, Ph.D.; Patricia Bernardo, Sc.D.; Barbara McGovern, MD; John G. Aunins, Ph.D.; David N. Cook, Ph.D.; Michele Trucksis, Ph.D., M.D.
2:45 PM
Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data
Saima Aslam, MD, MS; Timothy Gilbey, MD; Susan Maddocks, MD; Sandra Morales, PhD; Susan Lehman, PhD; Steven Branston, PhD; Aleksandra Petrovic Fabijan, PhD; Carrie-Lynn Langlais Furr, PhD; Francisco Rosas, MS/RAC; Igor Bilinsky, PhD; Paul Grint, MD; Robert T. Schooley, MD, FIDSA; Jonathan Iredell, Professor
3:00 PM
Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)
Lindsay Avery, PharmD; Joseph L. Kuti, PharmD; Maja Weisser, MD; Adrian Egli, MD; Michael J. Rybak, PharmD, MPH, PhD; Evan J. Zasowski, PharmD, MPH, BCPS; Cesar Arias, MD, PhD, FIDSA; German Contreras, MD; Pearlie Chong, MD, MSCR; Samuel L. Aitken, PharmD; Adam J. DiPippo, PharmD; Jann-Tay Wang, MD, PhD; Nicholas S. Britt, PharmD, MS; David P. Nicolau, PharmD, FCCP, FIDSA

CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.